Brief: Novonesis Expects 20204 Organic Sales Growth At Upper End Of 7-8% Range

Novozymes A/S

07/11/2024 07:11

Nov 7 (Reuters) - Novozymes A/S  NSISb.CO :
    * OUTLOOK 2024: YEAR-ON-YEAR, SECOND HALF OF YEAR IS
EXPECTED TO
GROW STRONGER THAN FIRST HALF
    * OUTLOOK 2024: NOW EXPECTS FULL-YEAR ORGANIC SALES GROWTH
TO BE
AT UPPER END OF 7-8% RANGE
    * OUTLOOK 2024: ADJUSTED EBITDA MARGIN IS CONFIRMED TO BE
BETWEEN
35.5-36.5%
    * OUTLOOK 2024: BOTH FOOD & HEALTH BIOSOLUTIONS AND
PLANETARY
HEALTH BIOSOLUTIONS ARE EXPECTED TO GROW AT AROUND SAME LEVEL AS
INDICATED FOR GROUP
    * NOVONESIS REALIZED 9% PRO FORMA ORGANIC SALES GROWTH FOR
FIRST
9M 2024 (Q3 11%)

Source text:  ID:nGNE2g2CHs 
Further company coverage:  NSISb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))